Navigation Links
Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia
Date:8/12/2009

WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Merck/Schering-Plough's Zetia and Vytorin have lost substantial patient share in second- and third-line therapy since last year's analysis of the dyslipidemia drug market. This decline is most likely attributed to the publication of the ENHANCE trial which called into question the ability of these agents to improve clinical outcomes beyond the ability of statin monotherapy.

The new Treatment Algorithms in Dyslipidemia report also finds that statins have gained patient share with Zetia's and Vytorin's decline in use since the ENHANCE fallout. Survey results indicate that over the next two years cardiologists and primary care physicians intend to be more aggressive in their treatment of dyslipidemia. They also plan to increase their use of the most potent statins, particularly Pfizer's Lipitor and AstraZeneca's Crestor, and adjunct agents belonging to the classes of fenofibrates and bile acid sequestrants.

"Our survey of physicians indicates that favorable results from the 2008 JUPITER trial are likely to increase the percentage of physicians prescribing Crestor in the first line and may lead to increases in Crestor's patient share. However, Crestor will have to compete with the availability of generic Lipitor in 2011 and AstraZeneca should try to gain as much traction as possible prior to the arrival of this additional competition," stated Amanda Puffer, M.Sc., analyst at Decision Resources.

By combining patient-level claims data with physician survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models.

Patient-flow analysis for dyslipidemia shows that a sizable percentage of second-line or later users of Abbott's Simcor switched to the drug from Vytorin, suggesting that Simcor may have benefited from concerns over the efficacy of Vytorin following the ENHANCE trial. Survey results indicate that Simcor will be increasingly incorporated into the treatment algorithm as a first-line agent and it could continue to steal share from Vytorin prior to the launch of emerging fixed-dose combinations such as Abbott/AstraZeneca's Certriad (Crestor/TriLipix FDC).

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. HCM Announces Substantial Growth in 2007
2. Excalibur Celebrates PIramed Sale With Substantial Cash Return to Investors
3. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
4. KJT Group Positions for Substantial Growth
5. Gerresheimer Substantially Increases Quarterly Operating Profit
6. Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
7. Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers Disease
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... ; Frankfurt Prime Standard: QIA) today announced the introduction ... for gene expression profiling, expanding QIAGEN,s portfolio of Sample ... enable researchers to select from over 20,000 human genes ... interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... CRUZ, Calif. , Feb. 11, 2016  Dovetail ... applications to its beta program for a planned metagenomic ... will present the company,s metagenomic genome assembly method in ... Advances in Genome Biology & Technology conference in ... assembly of these highly complex datasets is difficult. Using ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... stem cell treatment clinic in Quito, Ecuador. The new facility will provide advanced ... to patients from around the world. , The new GSCG clinic is ...
(Date:2/10/2016)... 2016 ASAE is introducing a hybrid membership ... (AMC) the option of joining or renewing through an ... by staff size, every employee in any size association ... reap all available member benefits.   John ... membership options will allow organizations of any size and ...
Breaking Biology Technology:
(Date:2/8/2016)... 2016 Worldcore is ... innovation for clients, comfort and unbeatable security, with ... --> Worldcore is the first EU-regulated ... comfort and unbeatable security, with a Voice Biometrics ... Worldcore is the first EU-regulated global payment ...
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/3/2016)... February 3, 2016 --> ... research report "Automated Fingerprint Identification System Market by Component ... Application (Banking & Finance, Government, Healthcare, and Transportation) and ... the market is expected to be worth USD 8.49 ... between 2015 and 2020. The transformation and technology evolution ...
Breaking Biology News(10 mins):